Craig Larson
Analyst · JMP Securities. Your line is now open
Yeah, Devin, it's Craig, let me spend a minute, really, I think, on the two things we'd highlight as relates to levels of activity and then can just speak very briefly geographically and this is through a private equity lens. I think the - when you look at our investment activity, you really see two things, and the first is you see us leaning into complexity. So we're focused on those opportunities where we can really bring our operational expertise to bear and either help reposition an investment or in some cases even restructure these investments. And so what are some examples of these, last quarter we talked about the Unilever transaction, carve outs are complicated and in global carve outs may even be probably even more complicated. And we have had a global team in that instance that evaluated this business, it operates in both developed and undeveloped markets. It's, again, just very complicated, there's a lot of complexity in terms of executing on an opportunity like that. Envision is an investment where we're going to be focused together with management on a series of operational improvement initiatives and BMC the mainframe industry, again, is certainly industry with complexity. So, complexity and operational improvements, that's the first thing. I think the second thing you see is, is really our activity in healthcare that that we view as, as being a more defensive - more defensive sector. So in the US, certainly it's an enormous market, healthcare spending accounts were around 18% of US GDP. It's growing, it's fragmented and we've been active. In private equity investments, this quarter, again, would include and Envision, if you think more broadly, over the last 18 months or so, Internet brands acquired acquisition of WebMD, we acquired Nature's Bounty, Air Medical acquired a company called American Medical Response. We formed a partnership with Walgreens to acquire for PharMerica. There's a pending additional investment as PharMerica announced a transaction with BrightSpring. So again, I think all of that helps give you a sense of how busy our team's been. Activities not limited just to private equity, so when our core strategy in 2018, we acquired a company called PetVet in Q1, Heartland dental in Q2. It's also not limited to just the US, we have a pending investment in Genesis Healthcare, it's one of the largest providers of cancer and cardiac care in Australia and Europe, is again, is within core. We've created a company called SinoCare in China, again, I think you get a sense of the level of activity in that sector for us. So I think where we are, you know, broadly in going by geographies in the Americas, I think the area of emphasis for us are going to be companies and sectors that are more defensive. Not every investments going to fit this profile, but certainly accurate in terms of what you've seen from us broadly. Asia, you're right, 2018 was an active deployment year for us and our backlog here is actually pretty healthy. Our team in China is busy. We've been seeing more control-oriented investments, which is exciting for us. And we're also seeing a greater number of conglomerate and carve out opportunities. So it feels like some companies have expanded in China have found its competitive, a unique environment and are now considering whether to rationalize and sell those businesses. So that's interesting for us. And in Europe, broadly, we're being disciplined given valuations. But we are seeing dislocation in the UK and most specifically. So hopefully that, again, gives you a sense of where we're active.